RxSight, Inc. announced preliminary unaudited financial results for Q4 and full-year 2025, with revenue expected to be $32.6 million and $134.5 million respectively. The company also reported the sale of 28,611 Light Adjustable Lenses and 25 Light Delivery Devices in Q4. Mark Wilterding has been appointed as the new Chief Financial Officer, bringing over 25 years of financial leadership experience to the role. The company’s full-year 2025 financial results will be announced in February. RxSight is focused on providing customized vision to patients post-cataract surgery with its adjustable intraocular lens technology.

Read more at GlobeNewswire: RxSight, Inc. Announces Preliminary Q4 and 2025 Financial